Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially… read more.
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery…. read more.
UBC researchers demonstrated in 2019 that pre-schoolers can safely overcome peanut allergies with a treatment called oral immunotherapy. Now they have evidence that the earlier pre-schoolers start this… read more.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and… read more.
A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack… read more.
University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.
Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis. Mycobacterium tuberculosis (Mtb)… read more.
One infusion of an investigative chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for multiple myeloma has produced early and durable responses in heavily pretreated patients, researchers reported… read more.
Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer… read more.
Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.
The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from Sanofi as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
